Aldeyra Therapeutics (ALDX) Expected to Announce Quarterly Earnings on Friday

Aldeyra Therapeutics (NASDAQ:ALDX) is expected to announce its Q4 2025 results before the market opens on Friday, February 27th. Analysts expect the company to announce earnings of ($0.14) per share and revenue of $24.25 million for the quarter. Parties are encouraged to explore the company’s upcoming Q4 2025 earning overview page for the latest details on the call scheduled for Monday, March 2, 2026 at 4:00 PM ET.

Aldeyra Therapeutics Stock Up 1.2%

NASDAQ ALDX opened at $5.08 on Friday. The firm has a market cap of $305.61 million, a P/E ratio of -6.96 and a beta of 0.98. Aldeyra Therapeutics has a 52-week low of $1.14 and a 52-week high of $7.20. The business’s 50-day moving average price is $4.98 and its 200 day moving average price is $5.17.

Analyst Upgrades and Downgrades

Separately, BTIG Research reiterated a “buy” rating and issued a $9.00 target price on shares of Aldeyra Therapeutics in a research note on Monday, November 10th. Two analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Hold” and a consensus price target of $9.50.

Institutional Trading of Aldeyra Therapeutics

Institutional investors have recently bought and sold shares of the company. Caption Management LLC increased its position in shares of Aldeyra Therapeutics by 110.6% in the second quarter. Caption Management LLC now owns 12,664 shares of the biotechnology company’s stock valued at $49,000 after buying an additional 132,358 shares in the last quarter. Global Retirement Partners LLC acquired a new stake in Aldeyra Therapeutics in the 4th quarter valued at about $52,000. CIBC Private Wealth Group LLC acquired a new stake in Aldeyra Therapeutics in the 3rd quarter valued at about $55,000. BNP Paribas Financial Markets increased its holdings in Aldeyra Therapeutics by 36.9% during the 3rd quarter. BNP Paribas Financial Markets now owns 10,610 shares of the biotechnology company’s stock valued at $55,000 after acquiring an additional 2,859 shares in the last quarter. Finally, Federation des caisses Desjardins du Quebec raised its position in Aldeyra Therapeutics by 25.8% during the fourth quarter. Federation des caisses Desjardins du Quebec now owns 12,187 shares of the biotechnology company’s stock worth $63,000 after acquiring an additional 2,500 shares during the last quarter. 59.71% of the stock is currently owned by hedge funds and other institutional investors.

Aldeyra Therapeutics Company Profile

Aldeyra Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel small molecule therapies for immune-mediated diseases. The company’s research efforts center on targeted alkenals, a class of reactive aldehyde species that play a key role in inflammatory pathways. By selectively modulating these pathways, Aldeyra aims to address both ocular and systemic indications with high unmet medical need.

The company’s lead product candidate, reproxalap, is being investigated in several ophthalmic disorders, including dry eye disease, allergic conjunctivitis and non-infectious anterior uveitis.